News
- Author:
- Andrew D. Bowser
Publish date: December 12, 2019
ORLANDO – The results support continued investigation in phase 3 trial for rozanolixizumab and efgartigimod, according to investigators.
News
- Author:
- Andrew D. Bowser
Publish date: December 12, 2019
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the America...
News
- Author:
- Andrew D. Bowser
Publish date: December 10, 2019
For predicting severe liver disease, investigators say today’s scoring systems lack precision in unselected populations with low prevalence of adva...
News
- Author:
- Andrew D. Bowser
Publish date: December 10, 2019
ORLANDO – The multicenter study was aimed at addressing the knowledge gap around what therapy to use after venetoclax.
News
- Author:
- Andrew D. Bowser
Publish date: December 8, 2019
ORLANDO – Imagine what that would be like to have a chronic, debilitating illness and to have to go to multiple different hospitals, during this vu...
News
- Author:
- Andrew D. Bowser
Publish date: December 7, 2019
ORLANDO – Liberalizing renal function eligibility criteria might promote recruitment of African Americans to AML ...
News
- Author:
- Andrew D. Bowser
Publish date: December 7, 2019
ORLANDO – Duration of response, manageable safety support further investigation of dual-targeted strategy, according to investigator.
News
- Author:
- Andrew D. Bowser
Publish date: December 6, 2019
The observation period was still relatively short, however so longer-term data may be needed to more fully characterize lipid impact and cardiovasc...
News
- Author:
- Andrew D. Bowser
Publish date: December 6, 2019
Cholestasis markers dropped in some, but not all, patients with primary sclerosing cholangitis and inflammatory bowel disease, though a prospective...
News
- Author:
- Andrew D. Bowser
Publish date: December 3, 2019
Compared with elective colonoscopy, recommended procedure resulted in no statistical difference in primary or key secondary outcome.
News
- Author:
- Andrew D. Bowser
Publish date: November 22, 2019
BOSTON – AASLD highlights included treatment of persons who inject drugs, new directions in pangenotypic therapy, ben...
News
- Author:
- Andrew D. Bowser
Publish date: November 21, 2019
Findings may have implications for genetic test development, investigators note.
News
- Author:
- Andrew D. Bowser
Publish date: November 21, 2019
BOSTON – Promising new data for cotadutide, licogliflozin, tropifexor, saroglitazar, and PF-05221304 highlighted in “...
News
- Author:
- Andrew D. Bowser
Publish date: November 20, 2019
BOSTON – With no approved pharmacologic treatments for NAFLD and NASH, weight reduction remains one of the mainstays of treatment.
News
- Author:
- Andrew D. Bowser
Publish date: November 20, 2019
New CDC recommendations intended to help HCPs pinpoint and manage vaping-associated lung injuries as seasonal respiratory infections trend upward.<...
